Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 364-372

  Yeh, Jwu Lai ^a   Hsu, Jong Hau ^a,b   Liang, Jyh Chong ^c   Chen, Ing Jun ^a   Liou, Shu Fen ^d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Dihydropyridine calcium channel blockers; Lipopolysaccharide interferon ; Vascular smooth muscle cells

Indexed keywords

ANTIINFLAMMATORY AGENT; DIHYDROPYRIDINE DERIVATIVE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LABEDIPINEDILOL A; LERCANIDIPINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NIFEDIPINE; NITRIC OXIDE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSOL; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; IMMUNOCYTOCHEMISTRY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASCULITIS; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; ANISOLES; ANTI-INFLAMMATORY AGENTS; DIHYDROPYRIDINES; HMGB1 PROTEIN; INFLAMMATION; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; RATS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84872421061     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.12.005     Document Type: Article

References (32)

1. Stoll L.L., Denning G.M., Weintraub N.L. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:2227-2236.
2. Cartwright N., Murch O., McMaster S.K., et al. Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am J Respir Crit Care Med 2007, 175:595-603.
3. Hsieh C.Y., Hsu M.J., Hsiao G., et al. Andrographolide enhances nuclear factor-kappaB subunit p65 Ser536 dephosphorylation through activation of protein phosphatase 2A in vascular smooth muscle cells. J Biol Chem 2011, 286:5942-5955.
4. Baeuerle P.A., Baichwal V.R. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997, 65:111-137.
5. Ishii N., Matsumura T., Shimoda S., Araki E. Anti-atherosclerotic potential of dihydropyridine calcium channel blockers. J Atheroscler Thromb 2012, 19:693-704.
6. Hernández R.H., Armas-Hernández M.J., Velasco M., Israili Z.H., Armas-Padilla M.C. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003, 10:409-414.
7. Nakano K., Egashira K., Ohtani K., et al. Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice. Atherosclerosis 2008, 196:172-179.
8. Ram C.V. Hypertension, possible vascular protection and lercanidipine. Expert Rev Cardiovasc Ther 2006, 4:783-788.
9. Taddei S., Ghiadoni L., Versari D., Salvetti G., Magagna A., Salvetti A. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003, 41:950-955.
10. Liou S.F., Wu J.R., Lai W.T., Sheu S.H., Chen I.J., Yeh J.L. The vasorelaxing action of labedipinedilol-A involves endothelial cell-derived NO and eNOS expression caused by calcium influx. J Cardiovasc Pharmacol 2005, 45:232-240.
11. Wu J.R., Liou S.F., Lin S.W., et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009, 59:48-56.
12. Liou S.F., Yeh J.L., Liang J.C., Chiu C.C., Lin Y.T., Chen I.J. Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-A through PKC and ERK 1/2 pathway. J Cardiovasc Pharmacol 2004, 44:539-551.
13. Hsu J.H., Wu J.R., Liou S.F., et al. Labedipinedilol-A prevents lysophosphatidylcholine-induced vascular smooth muscle cell death through reducing reactive oxygen species production and anti-apoptosis. Atherosclerosis 2011, 217:379-386.
14. Jeon S.B., Chun S., Choi-Kwon S., et al. Biomarkers and location of atherosclerosis: matrix metalloproteinase-2 may be related to intracranial atherosclerosis. Atherosclerosis 2012, 223:442-447.
15. Kaneko H., Anzai T., Morisawa M., et al. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis 2011, 217:350-357.
16. Kalinina N., Agrotis A., Antropova Y., et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004, 24:2320-2325.
17. Inoue K., Kawahara K., Biswas K.K., et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007, 16:136-143.
18. Andersson U., Wang H., Palmblad K., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000, 192:565-570.
19. Tsoyi K., Jang H.J., Nizamutdinova I.T., et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 2011, 162:1498-1508.
20. Jaulmes A., Thierry S., Janvier B., Raymondjean M., Maréchal V. Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta. FASEB J 2006, 20:1727-1729.
21. Chen G., Li J., Ochani M., et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol 2004, 76:994-1001.
22. Jiang W., Pisetsky D.S. The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid or lipopolysaccharide. J Immunol 2006, 177:3337-3343.
23. Kranzhöfer A., Baker A.H., George S.J., Newby A.C. Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein. Arterioscler Thromb Vasc Biol 1999, 19:255-265.
24. Rouis M., Adamy C., Duverger N., et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999, 100:533-540.
25. Hattori Y., Kasai K., Gross S.S. NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO. Cardiovasc Res 2004, 63:31-40.
26. Gómez-Hernández A., Martín-Ventura J.L., Sánchez-Galán E., et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. Atherosclerosis 2006, 187:139-149.
27. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003, 22:1313-1324.
28. Penzo M., Molteni R., Suda T., et al. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis. J Immunol 2010, 184:4497-4509.
29. Hattori Y., Hattori S., Kasai K. Lipopolysaccharide activates Akt in vascular smooth muscle cells resulting in induction of inducible nitric oxide synthase through nuclear factor-kappa B activation. Eur J Pharmacol 2003, 481:153-158.
30. Ishii N., Matsumura T., Kinoshita H., et al. Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2010, 30:1598-1605.
31. Severa M., D'Ambrosio A., Giordani L., Quintieri F., Coccia E. Inhibition of interleukin-12 expression in diltiazem-treated dendritic cells through the reduction of nuclear factor-kappa B transcriptional activity. Biochem Pharmacol 2005, 69:425-432.
32. Cuschieri J., Gourlay D., Garcia I., Jelacic S., Maier R.V. Slow channel calcium inhibition blocks proinflammatory gene signaling and reduces macrophage responsiveness. J Trauma 2002, 52:434-442.